Joshua H. Bilenker, M.D.

Dr. Bilenker is founder and chief executive officer of Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company. He joined Aisling Capital LLC, an investment firm, in 2006 and has served as an operating partner since 2013. From 2004 to 2006, Dr. Bilenker served as a medical officer at the U.S. Food and Drug Administration in the Office of Oncology. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his A.B. degree in English from Princeton University.